Revvity’s shares (currently trading at $111) have posted a disappointing 8.5% loss, well below the S&P 500’s 5.1% gain. This ...

Discover how Revvity's strategic acquisitions and financial improvements position it for long-term growth in cell and gene ...

Formerly known as PerkinElmer, Revvity (NYSE:RVTY) offers advanced diagnostic tools, scientific instruments, and services designed to support the pharmaceutical and biotechnology industries.

Revvity expects 2025 revenue to be in the range ... rose 4% to $393.2 million. Formerly known as PerkinElmer, the company divested three of its businesses in 2022 to focus on life sciences and ...

Revvity (RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce ...

(NYSE:RVTY) in its Q4 2024 investor letter: “Revvity, Inc. (NYSE:RVTY)—the former PerkinElmer—has been on a roller coaster ride the last few years. It generated windfall prohts from its ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on RVTY: PerkinElmer NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Bretton Fund stated the following regarding Revvity, Inc. (NYSE:RVTY) in its Q4 2024 investor letter: "Revvity, Inc. (NYSE:RVTY)—the former PerkinElmer—has been on a roller coaster ride the last few ...

Revvity, Inc. (NYSE: RVTY), announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life ...

Revvity, Inc. is set to unveil its new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity’s Harmony™ and Signals Image Artist™ ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor ...